Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Franck Emmanuel Nicolini , Stephanie Dulucq , Lisa Boureau , Pascale Cony-Makhoul , Aude Charbonnier , Martine Escoffre-Barbe , Francoise Rigal-Huguet , Valerie Coiteux , Bruno Varet , Viviane Dubruille , Pascal Lenain , Philippe Rousselot , Delphine Rea , Agnes Guerci-Bresler , Laurence Legros , Jixing Liu , Martine Gardembas , Jean-Christophe Ianotto , Pascal Turlure , Hyacinthe Johnson-Ansah , Juliana Martiniuc , Henry Jardel , Bertrand Joly , Patricia Zunic , Tawfiq Henni , Bruno Villemagne , Marc G. Berger , Emilie Cayssials , Francois Guilhot , Fabrice Larosa , Joelle Guilhot , Gabriel Etienne , Francois-Xavier Mahon Clinical cancer research（2019）
关键词
Treatment Discontinuation
AI 理解论文
溯源树
样例
